Dermatology

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1- Antihistamines
Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: LOU064 (blinded); Drug: Placebo; Drug: LOU064 (open-label)

Sponsors: Novartis Pharmaceuticals

Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 6, 2024Comments OffClinicalTrials.gov | Dermatology Clinical Trials | Dermatology Studies | US National Library of Medicine
A Clinical Trial to Evaluate the Effects of a Skin Balm on the Appearance of the Eye Area
Conditions: Skin Health

Interventions: Dietary Supplement: Experimental: Sahajan Golden Glow Balm

Sponsors: Sahajan; Citruslabs

Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 12, 2024Comments OffClinicalTrials.gov | Dermatology Clinical Trials | Dermatology Studies | US National Library of Medicine
Case-control Study on Matrix Metalloproteinase Levels in Tissue in Patients With Keloid Scar
Conditions: Keloid

Interventions: Procedure: Removal of Keloid

Sponsors: Henry Ford Health System

Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 1, 2024Comments OffClinicalTrials.gov | Dermatology Clinical Trials | Dermatology Studies | US National Library of Medicine
A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants
Conditions: Atopic Dermatitis

Interventions: Drug: Rocatinlimab vial injection; Combination Product: Rocatinlimab prefilled syringe

Sponsors: Amgen

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 20, 2024Comments OffClinicalTrials.gov | Dermatology Clinical Trials | Dermatology Studies | US National Library of Medicine
Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy
Conditions: Vitiligo; Dermatology/Skin – Other

Interventions: Device: Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet

Sponsors: Johns Hopkins University

Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 10, 2024Comments OffClinicalTrials.gov | Dermatology Clinical Trials | Dermatology Studies | US National Library of Medicine
Cold Atmospheric Plasma Device Extension Study
Conditions: Verruca Vulgaris; Molluscum Contagiosum

Interventions: Device: Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)

Sponsors: Medical University of South Carolina; The Skin Center Dermatology Group

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 20, 2023Comments OffClinicalTrials.gov | Dermatology Clinical Trials | Dermatology Studies | US National Library of Medicine
Foam Tape Allergy a Sticky Situation
Conditions: Medical Adhesive Allergy; Dermatologic Conditions; Dermatologic Lesions

Interventions: Other: 2×2 inch piece of 3M microfoam adhesive

Sponsors: CHRISTUS Health

Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 29, 2023Comments OffClinicalTrials.gov | Dermatology Clinical Trials | Dermatology Studies | US National Library of Medicine
A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions

The study is a multi-center, longitudinal, observational study to describe longitudinal trajectories of Clinician-Reported Outcomes (ClinROs) and Patient-Reported Outcomes (PROs) in patients with select dermatological conditions. This study will collect data using validated clinical instruments and patient-reported data on the disease course of alopecia areata (AA), atopic dermatitis (AD), hidradenitis suppurativa (HS), psoriasis (PsO), and vitiligo (VL), including symptom assessments and quality of life (QoL) measures from a patient perspective, to supplement routine clinical data collected from their healthcare providers. ClinRO data will be collected at baseline and routine follow-up visits for up to two years. PRO data will be collected directly from patients at baseline and at pre-specified follow-up time points (as defined in Tables 1 – 2e) for up to two years.

The objectives of this study are:

  • To describe longitudinal changes in disease activity, symptom control and both physical and mental HrQoL based on both ClinROs and PROs
  • To identify patient, disease and treatment factors associated with changes in PROs over time
  • To describe the association between PROs, ClinROs and clinical outcomes

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 4, 2023Comments OffClinicalTrials.gov | Dermatology Clinical Trials | Dermatology Studies | US National Library of Medicine
VR-PAT for Pain and Anxiety Management During Pediatric Dermatologic Laser Procedures

Recruitment Status

warningThe safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05056168
Recruitment Status : **RECRUITING NOW**

First Posted : September 24, 2021

Last Update Posted : December 15, 2022

PsoriasisOther: Dermatology-Specific Treatment Satisfaction Instrument

Layout table for study information
Study Type :Observational
Estimated Enrollment :120 participants
Observational Model:Cohort
Time Perspective:Prospective
Official Title:Validation of a Dermatology-Specific Treatment Satisfaction Instrument
Actual Study Start Date :November 13, 2021
Estimated Primary Completion Date :March 2023
Estimated Study Completion Date :May 2023

Layout table for eligibility information
Ages Eligible for Study:  18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:  All
Accepts Healthy Volunteers:  No
Sampling Method:  Non-Probability Sample

Layout table for location information
University of Southern California
Los Angeles, California, United States, 90089
Contact: Gina Kostandy, MPH    323-865-3641    gina.kostandy@med.usc.edu   
Principal Investigator: April W Armstrong, MD, MPH         

Layout table for investigator information
Principal Investigator:April Armstrong, MD, MPHUniversity of Southern California
Layout table for additonal information
Responsible Party:April Armstrong, Professor, University of Southern California
ClinicalTrials.gov Identifier:NCT05056168    
Other Study ID Numbers:HS-18-00891-AM004
First Posted:September 24, 2021    Key Record Dates
Last Update Posted:December 15, 2022
Last Verified:December 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product:No
Studies a U.S. FDA-regulated Device Product:No

Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases